Tel Aviv University

Bar-ilan University

Biolinerx Ltd.

Irit Gil-Ad

Abraham Nudelman

Ada Rephaeli

Abraham Weizman

Moshe Portnoy

Efrat Halbfinger

Mazal Shaul

Avraham Weizman

Gideon Stein

Yona Geffen

Kinneret Savitsky

Ran Lifshitz

Ilan Winkler

Shlomit Halachmi

Eran J Benjamin

Methods and articles of manufacture for use in improving a cognitive function, utilizing a conjugate comprising a first moiety having GABA agonist activity and a second moiety having CNS activity being covalently linked to the first moiety, are disclosed. Also disclosed are methods and articles of manufacture of preventing onset or inhibiting progression of a cognitive impairment or dysfunction utilizing the disclosed conjugate.

Methods of improving cognitive functions

An acid addition salt of a nortriptyline-GABA conjugate, a novel crystalline form of a fumaric acid addition salt of a nortriptyline-GABA conjugate, and processes of preparing the forgoing are disclosed. Uses of the above-indicated forms of a nortriptyline-GABA conjugate in the treatment of CNS disorders, and in the treatment of pain in particular, are also disclosed. Further disclosed in a large-scale process of preparing a nortriptyline-GABA conjugate.

Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same

The invention provides novel compounds and pharmaceutical compositions for the treatment of psychological and/or psychiatric diseases or disorders.

Psychotropic agents having glutamate NMDA activity

A conjugate comprising L-DOPA covalently linked to at least one &#x3b3;-aminobutyric acid (GABA) moiety, an ester and/or an addition salt thereof are disclosed, as well as uses thereof for treating a neurodegenerative disease or disorder.

Conjugates for treating neurodegenerative diseases and disorders

A novel use of conjugates of psychotropic drugs (e.g., antidepressants or anti-epileptic drugs) and organic acids such as GABA in the treatment of pain is disclosed. A novel GABA conjugate and uses thereof is also disclosed.

Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders

Novel crystalline form of perphenazine 4-aminobutyrate trimesylate and a process of producing the same are disclosed. The novel crystalline form is characterized by a unique XRPD pattern and a DSC that exhibits an endothermic peak at a relatively high temperature (e.g., higher than 209&#xb0; C.). Also disclosed are a process of preparing perphenazine 4-aminobutyrate trimesylate by in situ deprotection and salification, in a single-step synthesis, and a highly pure perphenazine 4-aminobutyrate trimesylate obtained thereby. Uses of any of the described perphenazine 4-aminobutyrate trimesylate are also disclosed.

Crystalline forms of the tri-mesylate salt of perphenazine-GABA and process of producing the same

Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.

Conjugated psychotropic drugs and uses thereof

Conjugates of a gamma-aminobutyric acid (GABA) compound or a glycine compound and an analgesic drug are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses thereof in the treatment of CNS-associated diseases or disorders, optionally in combination with a psychotropic drug.

Growing community of inventors

Herzlia, Israel

Irit Gil-Ad